If a compound shows real promise in the research, why doesn’t it become a medicine? Most people assume the answer is about safety or whether it works. Tony Huge’s video argues that Big Pharma applies a second filter that has almost nothing to do with the science: patents. He walks through what drug approval costs, why a company will only pay it for something it can own, and why that leaves an entire category of unpatentable compounds stuck in what health economists call the valley of death. Then he does something unusual for this genre. He tells you how to spot when a real economic fact is being dressed up as a conspiracy.
Video: Why Big Pharma Won’t Fund Cures It Can’t Patent (The $3B Problem). Published July 23, 2026. Watch on YouTube.
What the video covers
Timestamps marked with ~ are estimated from the transcript; the description’s chapter markers do not match this six-minute cut.
- ~00:00 The simple question: Why promising compounds do not become medicines, and the second filter nobody explains.
- ~00:45 What approval costs: One to three billion dollars, 10 to 15 years, and fewer than 12% of candidates entering human trials making it through.
- ~01:35 The one guarantee: A 20-year patent monopoly is the only way a company can be confident of recovering that spend.
- ~02:10 The gap: Naturally occurring compounds are very hard to patent, so a competitor can copy them the day after approval.
- ~03:10 Three documented examples: Vitamin D, off-patent generics and naturally derived peptides.
- ~04:05 The valley of death: Four things that can happen to an unpatentable compound, including the biotech workaround.
- ~05:10 Two claims that sound alike: Unfunded versus suppressed, and why the difference matters for every health video you watch.
The approval economy, in three numbers
Tony cites widely used analysis, including work from the Tufts Center for the Study of Drug Development, putting the average cost of bringing a new drug to market at between one and three billion dollars. The process takes 10 to 15 years: preclinical work, three phases of human trials, then regulatory review. And most candidates fail. Industry estimates he cites put the share of drugs entering human trials that ever reach approval at under 12%.
That last number is the one that drives everything else. A drug that succeeds is not just paying for itself. It is paying for every candidate that died along the way. So the survivors have to be extremely profitable, and a company will only take on that risk if it is confident of getting the money back. There is exactly one mechanism that provides that confidence: a patent, a 20-year legal monopoly during which nobody else can sell the same compound.
Why the molecule’s origin decides its fate
Patents are granted for novel compounds. New, synthetic, engineered. That model works well for a large share of modern medicine. The gap Tony wants you to see is on the other side of the line. If a molecule already exists in nature, in the body or in a plant, and it has not been meaningfully modified, patent offices generally will not grant exclusive rights to it. So even if it is safe, even if it works, the moment it is approved any competitor can manufacture it and undercut the price.
He asks you to sit in the pharmaceutical company’s chair for a moment. Would you spend two to three billion dollars and 15 years developing something a competitor can copy the day after approval? For most companies the honest financial answer is no. Not because the compound is bad, but because the math does not close.
“This isn’t hypothetical. This is a documented, real pharmaceutical economics lesson.”
Tony Huge, ~03:05
Three places you can watch it happen
Tony gives three documented examples. Vitamin D: studies have explored links between vitamin D status and reduced risk in certain conditions, but the natural form has never been exclusively patented, so large industry-funded trials have been comparatively rare next to synthetic drugs targeting similar pathways. Off-patent generics: once a patent expires, funding for new trials exploring additional uses drops off sharply, even where researchers suspect real potential, because there is no exclusivity left to fund them. Naturally derived peptides and compounds: molecules the body already makes, or close natural analogs, fall into the same trap. The early research looks promising in the published literature, but with no patentable modified version, no company has a reason to fund the billion-dollar trial process.
The valley of death
Health economists have a name for the gap between promising early research and the funding needed to cross into full clinical approval: the valley of death. Tony lays out the four things that can happen to a compound that lands there.
Some stay in early research indefinitely. Peer-reviewed papers keep coming, sometimes for decades, without any large human trial, simply because nobody is funding the next stage. Some get picked up by public academic funding, which fills part of the gap but almost never at the scale full drug development requires. Some get rescued by a smaller biotech that creates a patentable modified version, a tweaked structure or a new delivery method, specifically so it becomes patent-eligible. Tony is clear that this is common and legitimate. And some simply stay stuck: interesting, published, unavailable, possibly for a very long time.
That, in his telling, is the structural reason a lot of promising research never becomes a prescription. Not because anyone is hiding it. Because the system that funds drug development was built around patentable innovation, and compounds that do not fit the model fall through the cracks.
Why this protects you from the next video
The turn at the end is what makes this one worth the six minutes. A lot of health content takes this real economic gap and inflates it into a story about doctors and regulators deliberately hiding cures. Tony gives you two claims to hold side by side.
Claim one: this compound has not been through large human trials because there is no patent incentive to fund them, so its long-term safety profile is genuinely unknown. That claim is accurate and evidence-based. Claim two: your doctor knows this works but is not allowed to tell you because the system is corrupt. That is a much bigger claim wearing a real economic fact as a costume to sound credible.
The economics are real. The funding gap is real. But unfunded is not the same as suppressed, and not yet proven safe in humans is not the same as proven and hidden. He tells you to remember the difference the next time a video promises a cure that nobody wants you to know about, and he says out loud that the rule applies to his own channel too.
Cheat Sheet Pivot
The takeaways Tony lays out, framed as the reasoning he wants you to apply rather than anything to take.
- The figures he cites: one to three billion dollars per approved drug, 10 to 15 years, under 12% of human-trial entrants approved, and a 20-year patent as the only guaranteed recovery mechanism.
- A compound’s patent status, not its safety data, is often what decides whether the trials get run.
- The valley of death has four exits: indefinite early research, partial academic funding, a patentable biotech modification, or staying stuck.
- When a research compound has hundreds of animal studies and no large human trials, Tony’s honest reading is “unfunded, long-term safety unknown,” not “suppressed and proven.”
- Any video, including his, that jumps from the funding gap to a hidden cure has swapped an economic fact for a conspiracy claim.
The compounds this filter touches most, the naturally derived peptides, are catalogued in the Miracle Molecules Cheat Sheet. For the regulatory side of the same story, read The FDA Peptide Crackdown: Regulatory Capture, Not Patient Safety, and for a worked example of a compound with hundreds of animal studies and thin human data, see BPC-157 Explained: Rat Studies, Human Data and Trade-Offs.
Where the evidence stops
The cost, timeline and success-rate figures are industry estimates and widely cited analyses, not something Tony verified independently, and he presents them as such. The three examples are described as patterns, not as specific trials that were cancelled for patent reasons. The video does not claim any particular compound would have passed trials if funded; its argument is narrower and stronger, that the trials often do not get run, so we do not know.
The video also does not argue that regulators act in bad faith. Its position is that the incentive structure produces the gap on its own, which is precisely why the conspiracy framing is unnecessary.
Keep going
For Tony’s longer argument about why society treats healing compounds as threats, read The Hypocrisy of Anti-Peptide Hysteria. New companion articles reach the tonyhuge.is email list first, and the rest of the archive is on tonyhuge.is.